Romosozumab for the treatment of postmenopausal women at high risk of fracture
Open Access
- 5 December 2022
- journal article
- research article
- Published by Taylor & Francis in Expert Opinion on Biological Therapy
- Vol. 23 (1) , 11-19
Abstract
Romosozumab is a monoclonal antibody that binds to sclerostin (an inhibitor of the Wingless-related integration site (Wnt) signaling pathway). It is a new osteoanabolic drug, that simultaneously in...Keywords
This publication has 83 references indexed in Scilit:
- Single- and Multiple-Dose Randomized Studies of Blosozumab, a Monoclonal Antibody Against Sclerostin, in Healthy Postmenopausal WomenJournal of Bone and Mineral Research, 2013
- Myeloma cells suppress osteoblasts through sclerostin secretionBlood Cancer Journal, 2011
- Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male ratsJournal of Bone and Mineral Research, 2010
- Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strengthJournal of Bone and Mineral Research, 2010
- Teriparatide or Alendronate in Glucocorticoid-Induced OsteoporosisNew England Journal of Medicine, 2007
- Residual Lifetime Risk of Fractures in Women and MenJournal of Bone and Mineral Research, 2007
- Risk Factors for a First-Incident Radiographic Vertebral Fracture in Women 65 Years of Age: The Study of Osteoporotic FracturesJournal of Bone and Mineral Research, 2005
- Recombinant Human Parathyroid Hormone (1–34) [Teriparatide] Improves Both Cortical and Cancellous Bone StructureJournal of Bone and Mineral Research, 2003
- Epidemiology of fractures in England and WalesBone, 2001
- LDL Receptor-Related Protein 5 (LRP5) Affects Bone Accrual and Eye DevelopmentCell, 2001